. 2018 Feb 9;24:818–826. doi: 10.12659/MSM.906274

Table 4.

Comparison of FA composition in adipose tissue between patients with kidney stones and the control group.

FA (provided by percentage of total amount)	Patients (n=71)		Controls^## (n=100)	P value
	Without MS^* (n=48)	With MS^# (n=23)	Controls^## (n=100)
	Mean ± Standard deviation
C 18: 1×ω^**9	40.79±7.52	43.77±4.61	22.71±3.69	^,#p=0.041* ^*,##;#,##p<0.0001
C 20: 1ω9	1.26±0.80	0.92±0.35	0.56±0.48	^,#p=0.199 ^,##;#,##p<0.0001
C 18: 3ω3	0.22±0.17	0.21±0.13	1.12±0.54	^,#p=0.858 ^,##;#,##p<0.0001
C 22: 5ω3	0.23±0.23	0.21±0.17	0.39±0.27	^,#p=0.941 ^,##;#,##p<0.0001
Ratio of ω3/ω6	0.05±0.03	0.05±0.02	1.13±0.28	^,#p=0.912 ^,##;#,##p<0.0001
Total SFA (C 14: 0 + C 16: 0 + C 18: 0)	34.54±3.89	33.62±2.88	32.14±5.29	^,#p=1.0 ^,##p=0.008 ^#,##p=0.518
Total MUFA	51.04±4.93	52.30±3.91	26.19±4.27	^,#p=0.762 ^,##;#,##p<0.0001
Total PUFA	14.42±3.08	14.07±3.78	35.13±4.84	^,#p=1.0 ^,##;#,##p<0.0001
Ratio of PUFA/SFA	0.42±0.1	0.42±0.13	1.13±0.29	^,#p=1.0 ^,##;#,##p<0.0001
∑^***ω3	0.76±0.58	0.72±0.52	4.5±1.46	^,#p=1.0 ^,##;#,##p<0.0001
∑ ω6	13.67±2.82	13.36±3.34	27.91±4.56	^,#p=1.0 ^,##;#,##p<0.0001
C 14: 0	3.8±1.13	3.3±0.81	4.49±2.34	^,#p=1.0 ^,##p=0.124 ^#,##p=0.029
C 16: 0	25.01±2.51	24.94±2.05	21.9±2.4	^,#p=1.0 ^,##;#,##p<0.0001
C 18: 0	5.72±1.44	5.38±1.1	6.49±1.05	^,#p=0.709 ^,###,##p<0.0001
C 16: 1ω7	6.23±2.41	5.03±1.65	3.48±0.99	^,#p=0.003* ^*,##;#,##p<0.0001
C 18: 2ω6	13.25±2.7	13.02±3.2	22.59±3.98	^,##p=1.0 ^,##;#,##p<0.0001
C 20: 4ω6	0.42±0.3	0.34±0.23	5.33±1.11	^,#p=1.0 ^,##;#,##p<0.0001
C 20: 5ω3	0.11±0.07	0.1±0.08	1.06±0.68	^,##p=1.0 ^,##;#,##p<0.0001
C 22: 6ω3	0.19±0.15	0.19±0.17	1.92±0.73	^,#p=1.0 ^,##;#,##p<0.0001

SFA – saturated fatty acids; MUFA – monounsaturated fatty acids; PUFA – polyunsaturated fatty acids; ^* – kidney stone patients without MS; ^# – kidney stone patients with MS; ^## – control group; C 18: 1× – number of carbon atoms and double bonds; ω^** – position of double bond between carbon atoms in the molecule; ∑^*** – total sum.